Treatments for diseases affecting the hypothalamic-pituitary-adrenal (HPA) axis
Total Trials
6
As Lead Sponsor
As Collaborator
0
Total Enrollment
323
NCT03257462
Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia
Phase: Phase 2
Role: Lead Sponsor
Start: Jul 12, 2017
Completion: Mar 29, 2019
NCT03687242
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
Start: Sep 6, 2018
Completion: Aug 9, 2019
NCT04457336
A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH
Start: Aug 26, 2020
Completion: May 23, 2024
NCT04544410
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
Start: Feb 22, 2021
Completion: Jan 31, 2025
NCT05128942
A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children with CAH
Start: Dec 10, 2021
NCT05370521
A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
Start: May 15, 2022
Completion: Aug 31, 2023
Loading map...